Overview

A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome

Status:
Active, not recruiting

Trial end date:
2024-03-01

Target enrollment:

Participant gender:

Summary

This is a two-part, multicenter, double-blind, parallel-group, placebo controlled study to evaluate the effect of ZX008 when used as adjunctive therapy for the treatment of uncontrolled seizures in children and adults with Lennox-Gastaut syndrome (LGS).

Phase:

Phase 3

Details

Lead Sponsor:

Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.

Treatments:

Fenfluramine
Pharmaceutical Solutions